nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—Nateglinide—Bortezomib—hematologic cancer	0.114	0.258	CrCrCtD
Amphetamine—Aspartame—Bortezomib—hematologic cancer	0.108	0.245	CrCrCtD
Amphetamine—Lacosamide—Bortezomib—hematologic cancer	0.108	0.245	CrCrCtD
Amphetamine—SLC22A3—Melphalan—hematologic cancer	0.0877	0.291	CbGbCtD
Amphetamine—Phenacemide—Vorinostat—hematologic cancer	0.0863	0.195	CrCrCtD
Amphetamine—CYP2A6—Methoxsalen—hematologic cancer	0.0322	0.107	CbGbCtD
Amphetamine—SLC22A3—Irinotecan—hematologic cancer	0.0297	0.0985	CbGbCtD
Amphetamine—SLC22A3—Vincristine—hematologic cancer	0.026	0.0861	CbGbCtD
Amphetamine—L-Phenylalanine—Melphalan—hematologic cancer	0.0254	0.0574	CrCrCtD
Amphetamine—CYP2A6—Ifosfamide—hematologic cancer	0.0235	0.078	CbGbCtD
Amphetamine—CYP2A6—Prednisolone—hematologic cancer	0.0157	0.052	CbGbCtD
Amphetamine—CYP2D6—Lomustine—hematologic cancer	0.0146	0.0485	CbGbCtD
Amphetamine—CYP2D6—Idarubicin—hematologic cancer	0.013	0.0432	CbGbCtD
Amphetamine—CYP2D6—Hydroxyurea—hematologic cancer	0.0111	0.0367	CbGbCtD
Amphetamine—CYP2D6—Bortezomib—hematologic cancer	0.00964	0.032	CbGbCtD
Amphetamine—CYP2A6—Dexamethasone—hematologic cancer	0.00923	0.0306	CbGbCtD
Amphetamine—CYP2D6—Imatinib—hematologic cancer	0.00706	0.0234	CbGbCtD
Amphetamine—CYP2D6—Nilotinib—hematologic cancer	0.00642	0.0213	CbGbCtD
Amphetamine—CYP2D6—Vinorelbine—hematologic cancer	0.00636	0.0211	CbGbCtD
Amphetamine—CARTPT—hematopoietic system—hematologic cancer	0.004	0.12	CbGeAlD
Amphetamine—CYP2D6—Vinblastine—hematologic cancer	0.00392	0.013	CbGbCtD
Amphetamine—CYP2D6—Dexamethasone—hematologic cancer	0.0029	0.00963	CbGbCtD
Amphetamine—CARTPT—blood—hematologic cancer	0.00265	0.0793	CbGeAlD
Amphetamine—CYP2D6—Doxorubicin—hematologic cancer	0.00241	0.00799	CbGbCtD
Amphetamine—TAAR1—lung—hematologic cancer	0.00232	0.0695	CbGeAlD
Amphetamine—CARTPT—testis—hematologic cancer	0.00219	0.0656	CbGeAlD
Amphetamine—CARTPT—lymph node—hematologic cancer	0.00159	0.0475	CbGeAlD
Amphetamine—SLC18A2—hematopoietic system—hematologic cancer	0.00136	0.0407	CbGeAlD
Amphetamine—SLC6A3—hematopoietic system—hematologic cancer	0.00103	0.0308	CbGeAlD
Amphetamine—SLC22A3—hematopoietic system—hematologic cancer	0.000967	0.029	CbGeAlD
Amphetamine—SLC6A4—hematopoietic system—hematologic cancer	0.000941	0.0282	CbGeAlD
Amphetamine—SLC18A2—blood—hematologic cancer	0.0009	0.0269	CbGeAlD
Amphetamine—MAOB—hematopoietic system—hematologic cancer	0.000895	0.0268	CbGeAlD
Amphetamine—SLC18A2—lung—hematologic cancer	0.000789	0.0236	CbGeAlD
Amphetamine—SLC18A2—testis—hematologic cancer	0.000744	0.0223	CbGeAlD
Amphetamine—SLC22A3—gonad—hematologic cancer	0.000735	0.022	CbGeAlD
Amphetamine—CYP2A6—lung—hematologic cancer	0.000705	0.0211	CbGeAlD
Amphetamine—SLC6A2—gonad—hematologic cancer	0.00063	0.0189	CbGeAlD
Amphetamine—SLC6A4—blood—hematologic cancer	0.000624	0.0187	CbGeAlD
Amphetamine—SLC6A3—lung—hematologic cancer	0.000597	0.0179	CbGeAlD
Amphetamine—MAOB—blood—hematologic cancer	0.000593	0.0178	CbGeAlD
Amphetamine—SLC6A3—testis—hematologic cancer	0.000563	0.0169	CbGeAlD
Amphetamine—SLC22A3—lung—hematologic cancer	0.000562	0.0168	CbGeAlD
Amphetamine—SLC6A4—lung—hematologic cancer	0.000547	0.0164	CbGeAlD
Amphetamine—SLC18A2—lymph node—hematologic cancer	0.00054	0.0162	CbGeAlD
Amphetamine—SLC22A3—testis—hematologic cancer	0.00053	0.0159	CbGeAlD
Amphetamine—MAOB—lung—hematologic cancer	0.00052	0.0156	CbGeAlD
Amphetamine—MAOB—testis—hematologic cancer	0.000491	0.0147	CbGeAlD
Amphetamine—SLC6A2—lung—hematologic cancer	0.000481	0.0144	CbGeAlD
Amphetamine—SLC22A5—blood—hematologic cancer	0.000466	0.014	CbGeAlD
Amphetamine—SLC6A2—testis—hematologic cancer	0.000454	0.0136	CbGeAlD
Amphetamine—CYP2D6—hematopoietic system—hematologic cancer	0.000454	0.0136	CbGeAlD
Amphetamine—DRD2—lung—hematologic cancer	0.000439	0.0131	CbGeAlD
Amphetamine—DRD2—testis—hematologic cancer	0.000414	0.0124	CbGeAlD
Amphetamine—SLC22A5—lung—hematologic cancer	0.000409	0.0122	CbGeAlD
Amphetamine—SLC22A5—testis—hematologic cancer	0.000385	0.0115	CbGeAlD
Amphetamine—SLC22A3—lymph node—hematologic cancer	0.000384	0.0115	CbGeAlD
Amphetamine—MAOB—lymph node—hematologic cancer	0.000356	0.0106	CbGeAlD
Amphetamine—Pseudoephedrine—IL2—hematologic cancer	0.000353	0.344	CrCbGaD
Amphetamine—SLC6A2—lymph node—hematologic cancer	0.000329	0.00986	CbGeAlD
Amphetamine—CYP2D6—blood—hematologic cancer	0.000301	0.009	CbGeAlD
Amphetamine—SLC22A5—lymph node—hematologic cancer	0.000279	0.00836	CbGeAlD
Amphetamine—Phenformin—SLC22A1—hematologic cancer	0.000255	0.249	CrCbGaD
Amphetamine—CYP2D6—testis—hematologic cancer	0.000249	0.00745	CbGeAlD
Amphetamine—Lacosamide—CA9—hematologic cancer	0.000207	0.202	CrCbGaD
Amphetamine—Pseudoephedrine—TNF—hematologic cancer	0.000119	0.116	CrCbGaD
Amphetamine—Selegiline—ABCB1—hematologic cancer	4.69e-05	0.0458	CrCbGaD
Amphetamine—Nateglinide—ALB—hematologic cancer	4.39e-05	0.0429	CrCbGaD
Amphetamine—Insomnia—Triamcinolone—hematologic cancer	4.37e-05	0.000287	CcSEcCtD
Amphetamine—Gastrointestinal pain—Etoposide—hematologic cancer	4.35e-05	0.000286	CcSEcCtD
Amphetamine—Infection—Betamethasone—hematologic cancer	4.35e-05	0.000286	CcSEcCtD
Amphetamine—Infection—Dexamethasone—hematologic cancer	4.35e-05	0.000286	CcSEcCtD
Amphetamine—Dizziness—Vincristine—hematologic cancer	4.34e-05	0.000285	CcSEcCtD
Amphetamine—Rash—Carmustine—hematologic cancer	4.34e-05	0.000285	CcSEcCtD
Amphetamine—Dermatitis—Carmustine—hematologic cancer	4.33e-05	0.000285	CcSEcCtD
Amphetamine—Vomiting—Alitretinoin—hematologic cancer	4.33e-05	0.000285	CcSEcCtD
Amphetamine—Headache—Carmustine—hematologic cancer	4.31e-05	0.000283	CcSEcCtD
Amphetamine—Dyspnoea—Triamcinolone—hematologic cancer	4.3e-05	0.000283	CcSEcCtD
Amphetamine—Rash—Alitretinoin—hematologic cancer	4.3e-05	0.000282	CcSEcCtD
Amphetamine—Agitation—Prednisone—hematologic cancer	4.29e-05	0.000282	CcSEcCtD
Amphetamine—Dermatitis—Alitretinoin—hematologic cancer	4.29e-05	0.000282	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	4.29e-05	0.000282	CcSEcCtD
Amphetamine—Vomiting—Ifosfamide—hematologic cancer	4.28e-05	0.000281	CcSEcCtD
Amphetamine—Hypersensitivity—Cisplatin—hematologic cancer	4.28e-05	0.000281	CcSEcCtD
Amphetamine—Tachycardia—Dexamethasone—hematologic cancer	4.27e-05	0.000281	CcSEcCtD
Amphetamine—Tachycardia—Betamethasone—hematologic cancer	4.27e-05	0.000281	CcSEcCtD
Amphetamine—Headache—Alitretinoin—hematologic cancer	4.27e-05	0.000281	CcSEcCtD
Amphetamine—Angioedema—Prednisone—hematologic cancer	4.27e-05	0.000281	CcSEcCtD
Amphetamine—Diarrhoea—Gemcitabine—hematologic cancer	4.26e-05	0.00028	CcSEcCtD
Amphetamine—Nausea—Thalidomide—hematologic cancer	4.26e-05	0.00028	CcSEcCtD
Amphetamine—Dyspepsia—Triamcinolone—hematologic cancer	4.25e-05	0.000279	CcSEcCtD
Amphetamine—Rash—Ifosfamide—hematologic cancer	4.25e-05	0.000279	CcSEcCtD
Amphetamine—Dermatitis—Ifosfamide—hematologic cancer	4.24e-05	0.000279	CcSEcCtD
Amphetamine—Erythema multiforme—Methotrexate—hematologic cancer	4.24e-05	0.000279	CcSEcCtD
Amphetamine—Hyperhidrosis—Betamethasone—hematologic cancer	4.23e-05	0.000278	CcSEcCtD
Amphetamine—Hyperhidrosis—Dexamethasone—hematologic cancer	4.23e-05	0.000278	CcSEcCtD
Amphetamine—Dizziness—Irinotecan—hematologic cancer	4.23e-05	0.000278	CcSEcCtD
Amphetamine—Urticaria—Etoposide—hematologic cancer	4.23e-05	0.000278	CcSEcCtD
Amphetamine—Abdominal pain—Etoposide—hematologic cancer	4.21e-05	0.000276	CcSEcCtD
Amphetamine—Body temperature increased—Etoposide—hematologic cancer	4.21e-05	0.000276	CcSEcCtD
Amphetamine—Urinary tract infection—Doxorubicin—hematologic cancer	4.21e-05	0.000276	CcSEcCtD
Amphetamine—Vomiting—Vincristine—hematologic cancer	4.18e-05	0.000274	CcSEcCtD
Amphetamine—Anorexia—Dexamethasone—hematologic cancer	4.17e-05	0.000274	CcSEcCtD
Amphetamine—Anorexia—Betamethasone—hematologic cancer	4.17e-05	0.000274	CcSEcCtD
Amphetamine—Urticaria—Prednisolone—hematologic cancer	4.17e-05	0.000274	CcSEcCtD
Amphetamine—Asthenia—Cisplatin—hematologic cancer	4.17e-05	0.000274	CcSEcCtD
Amphetamine—Fatigue—Triamcinolone—hematologic cancer	4.16e-05	0.000273	CcSEcCtD
Amphetamine—Sweating—Doxorubicin—hematologic cancer	4.15e-05	0.000273	CcSEcCtD
Amphetamine—Rash—Vincristine—hematologic cancer	4.14e-05	0.000272	CcSEcCtD
Amphetamine—Dermatitis—Vincristine—hematologic cancer	4.14e-05	0.000272	CcSEcCtD
Amphetamine—Headache—Vincristine—hematologic cancer	4.12e-05	0.00027	CcSEcCtD
Amphetamine—Nausea—Carmustine—hematologic cancer	4.09e-05	0.000269	CcSEcCtD
Amphetamine—Vomiting—Mitoxantrone—hematologic cancer	4.07e-05	0.000267	CcSEcCtD
Amphetamine—Vomiting—Irinotecan—hematologic cancer	4.07e-05	0.000267	CcSEcCtD
Amphetamine—Nausea—Alitretinoin—hematologic cancer	4.05e-05	0.000266	CcSEcCtD
Amphetamine—Convulsion—Prednisone—hematologic cancer	4.05e-05	0.000266	CcSEcCtD
Amphetamine—Hypertension—Prednisone—hematologic cancer	4.03e-05	0.000265	CcSEcCtD
Amphetamine—Rash—Irinotecan—hematologic cancer	4.03e-05	0.000265	CcSEcCtD
Amphetamine—Rash—Mitoxantrone—hematologic cancer	4.03e-05	0.000265	CcSEcCtD
Amphetamine—Dermatitis—Irinotecan—hematologic cancer	4.03e-05	0.000265	CcSEcCtD
Amphetamine—Dermatitis—Mitoxantrone—hematologic cancer	4.03e-05	0.000265	CcSEcCtD
Amphetamine—Headache—Mitoxantrone—hematologic cancer	4.01e-05	0.000263	CcSEcCtD
Amphetamine—Headache—Irinotecan—hematologic cancer	4.01e-05	0.000263	CcSEcCtD
Amphetamine—Nausea—Ifosfamide—hematologic cancer	4e-05	0.000263	CcSEcCtD
Amphetamine—Diarrhoea—Cisplatin—hematologic cancer	3.97e-05	0.000261	CcSEcCtD
Amphetamine—Erythema multiforme—Epirubicin—hematologic cancer	3.97e-05	0.000261	CcSEcCtD
Amphetamine—Anxiety—Prednisone—hematologic cancer	3.96e-05	0.00026	CcSEcCtD
Amphetamine—Vomiting—Gemcitabine—hematologic cancer	3.96e-05	0.00026	CcSEcCtD
Amphetamine—Insomnia—Betamethasone—hematologic cancer	3.96e-05	0.00026	CcSEcCtD
Amphetamine—Insomnia—Dexamethasone—hematologic cancer	3.96e-05	0.00026	CcSEcCtD
Amphetamine—Rash—Gemcitabine—hematologic cancer	3.93e-05	0.000258	CcSEcCtD
Amphetamine—Dermatitis—Gemcitabine—hematologic cancer	3.93e-05	0.000258	CcSEcCtD
Amphetamine—Hypersensitivity—Etoposide—hematologic cancer	3.92e-05	0.000258	CcSEcCtD
Amphetamine—Headache—Gemcitabine—hematologic cancer	3.9e-05	0.000256	CcSEcCtD
Amphetamine—Nausea—Vincristine—hematologic cancer	3.9e-05	0.000256	CcSEcCtD
Amphetamine—Hypersensitivity—Prednisolone—hematologic cancer	3.87e-05	0.000254	CcSEcCtD
Amphetamine—Dyspepsia—Dexamethasone—hematologic cancer	3.86e-05	0.000253	CcSEcCtD
Amphetamine—Dyspepsia—Betamethasone—hematologic cancer	3.86e-05	0.000253	CcSEcCtD
Amphetamine—Urticaria—Triamcinolone—hematologic cancer	3.83e-05	0.000252	CcSEcCtD
Amphetamine—Asthenia—Etoposide—hematologic cancer	3.82e-05	0.000251	CcSEcCtD
Amphetamine—Body temperature increased—Triamcinolone—hematologic cancer	3.82e-05	0.000251	CcSEcCtD
Amphetamine—Anaphylactic shock—Prednisone—hematologic cancer	3.81e-05	0.000251	CcSEcCtD
Amphetamine—Decreased appetite—Dexamethasone—hematologic cancer	3.81e-05	0.00025	CcSEcCtD
Amphetamine—Decreased appetite—Betamethasone—hematologic cancer	3.81e-05	0.00025	CcSEcCtD
Amphetamine—Nausea—Irinotecan—hematologic cancer	3.8e-05	0.00025	CcSEcCtD
Amphetamine—Nausea—Mitoxantrone—hematologic cancer	3.8e-05	0.00025	CcSEcCtD
Amphetamine—Infection—Prednisone—hematologic cancer	3.79e-05	0.000249	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.78e-05	0.000248	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.78e-05	0.000248	CcSEcCtD
Amphetamine—Fatigue—Betamethasone—hematologic cancer	3.78e-05	0.000248	CcSEcCtD
Amphetamine—Fatigue—Dexamethasone—hematologic cancer	3.78e-05	0.000248	CcSEcCtD
Amphetamine—Tachycardia—Prednisone—hematologic cancer	3.72e-05	0.000245	CcSEcCtD
Amphetamine—Nausea—Gemcitabine—hematologic cancer	3.7e-05	0.000243	CcSEcCtD
Amphetamine—Vomiting—Cisplatin—hematologic cancer	3.69e-05	0.000243	CcSEcCtD
Amphetamine—Hyperhidrosis—Prednisone—hematologic cancer	3.69e-05	0.000242	CcSEcCtD
Amphetamine—Erythema multiforme—Doxorubicin—hematologic cancer	3.67e-05	0.000241	CcSEcCtD
Amphetamine—Rash—Cisplatin—hematologic cancer	3.66e-05	0.000241	CcSEcCtD
Amphetamine—Dermatitis—Cisplatin—hematologic cancer	3.66e-05	0.00024	CcSEcCtD
Amphetamine—Diarrhoea—Etoposide—hematologic cancer	3.64e-05	0.000239	CcSEcCtD
Amphetamine—Anorexia—Prednisone—hematologic cancer	3.64e-05	0.000239	CcSEcCtD
Amphetamine—Tension—Epirubicin—hematologic cancer	3.59e-05	0.000236	CcSEcCtD
Amphetamine—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.58e-05	0.000235	CcSEcCtD
Amphetamine—Gastrointestinal pain—Betamethasone—hematologic cancer	3.58e-05	0.000235	CcSEcCtD
Amphetamine—Hypersensitivity—Triamcinolone—hematologic cancer	3.56e-05	0.000234	CcSEcCtD
Amphetamine—Nervousness—Epirubicin—hematologic cancer	3.55e-05	0.000233	CcSEcCtD
Amphetamine—Dizziness—Etoposide—hematologic cancer	3.52e-05	0.000231	CcSEcCtD
Amphetamine—Urticaria—Betamethasone—hematologic cancer	3.48e-05	0.000229	CcSEcCtD
Amphetamine—Urticaria—Dexamethasone—hematologic cancer	3.48e-05	0.000229	CcSEcCtD
Amphetamine—Dizziness—Prednisolone—hematologic cancer	3.47e-05	0.000228	CcSEcCtD
Amphetamine—Asthenia—Triamcinolone—hematologic cancer	3.46e-05	0.000227	CcSEcCtD
Amphetamine—Body temperature increased—Dexamethasone—hematologic cancer	3.46e-05	0.000227	CcSEcCtD
Amphetamine—Body temperature increased—Betamethasone—hematologic cancer	3.46e-05	0.000227	CcSEcCtD
Amphetamine—Abdominal pain—Betamethasone—hematologic cancer	3.46e-05	0.000227	CcSEcCtD
Amphetamine—Abdominal pain—Dexamethasone—hematologic cancer	3.46e-05	0.000227	CcSEcCtD
Amphetamine—Nausea—Cisplatin—hematologic cancer	3.45e-05	0.000227	CcSEcCtD
Amphetamine—Insomnia—Prednisone—hematologic cancer	3.45e-05	0.000227	CcSEcCtD
Amphetamine—Convulsion—Methotrexate—hematologic cancer	3.38e-05	0.000222	CcSEcCtD
Amphetamine—Vomiting—Etoposide—hematologic cancer	3.38e-05	0.000222	CcSEcCtD
Amphetamine—Agitation—Epirubicin—hematologic cancer	3.36e-05	0.000221	CcSEcCtD
Amphetamine—Dyspepsia—Prednisone—hematologic cancer	3.36e-05	0.000221	CcSEcCtD
Amphetamine—Rash—Etoposide—hematologic cancer	3.36e-05	0.00022	CcSEcCtD
Amphetamine—Dermatitis—Etoposide—hematologic cancer	3.35e-05	0.00022	CcSEcCtD
Amphetamine—Headache—Etoposide—hematologic cancer	3.33e-05	0.000219	CcSEcCtD
Amphetamine—Chest pain—Methotrexate—hematologic cancer	3.32e-05	0.000218	CcSEcCtD
Amphetamine—Tension—Doxorubicin—hematologic cancer	3.32e-05	0.000218	CcSEcCtD
Amphetamine—Decreased appetite—Prednisone—hematologic cancer	3.32e-05	0.000218	CcSEcCtD
Amphetamine—Rash—Prednisolone—hematologic cancer	3.31e-05	0.000217	CcSEcCtD
Amphetamine—Dermatitis—Prednisolone—hematologic cancer	3.31e-05	0.000217	CcSEcCtD
Amphetamine—Fatigue—Prednisone—hematologic cancer	3.29e-05	0.000216	CcSEcCtD
Amphetamine—Headache—Prednisolone—hematologic cancer	3.29e-05	0.000216	CcSEcCtD
Amphetamine—Nervousness—Doxorubicin—hematologic cancer	3.28e-05	0.000216	CcSEcCtD
Amphetamine—Constipation—Prednisone—hematologic cancer	3.26e-05	0.000214	CcSEcCtD
Amphetamine—Palpitations—Epirubicin—hematologic cancer	3.23e-05	0.000212	CcSEcCtD
Amphetamine—Dizziness—Triamcinolone—hematologic cancer	3.19e-05	0.00021	CcSEcCtD
Amphetamine—Anaphylactic shock—Methotrexate—hematologic cancer	3.19e-05	0.000209	CcSEcCtD
Amphetamine—Convulsion—Epirubicin—hematologic cancer	3.17e-05	0.000208	CcSEcCtD
Amphetamine—Infection—Methotrexate—hematologic cancer	3.17e-05	0.000208	CcSEcCtD
Amphetamine—Nausea—Etoposide—hematologic cancer	3.16e-05	0.000208	CcSEcCtD
Amphetamine—Hypertension—Epirubicin—hematologic cancer	3.16e-05	0.000207	CcSEcCtD
Amphetamine—Asthenia—Betamethasone—hematologic cancer	3.14e-05	0.000206	CcSEcCtD
Amphetamine—Asthenia—Dexamethasone—hematologic cancer	3.14e-05	0.000206	CcSEcCtD
Amphetamine—Gastrointestinal pain—Prednisone—hematologic cancer	3.12e-05	0.000205	CcSEcCtD
Amphetamine—Nausea—Prednisolone—hematologic cancer	3.12e-05	0.000205	CcSEcCtD
Amphetamine—Chest pain—Epirubicin—hematologic cancer	3.11e-05	0.000204	CcSEcCtD
Amphetamine—Agitation—Doxorubicin—hematologic cancer	3.11e-05	0.000204	CcSEcCtD
Amphetamine—Anxiety—Epirubicin—hematologic cancer	3.1e-05	0.000204	CcSEcCtD
Amphetamine—Hyperhidrosis—Methotrexate—hematologic cancer	3.08e-05	0.000202	CcSEcCtD
Amphetamine—Vomiting—Triamcinolone—hematologic cancer	3.07e-05	0.000202	CcSEcCtD
Amphetamine—Rash—Triamcinolone—hematologic cancer	3.04e-05	0.0002	CcSEcCtD
Amphetamine—Dry mouth—Epirubicin—hematologic cancer	3.04e-05	0.0002	CcSEcCtD
Amphetamine—Dermatitis—Triamcinolone—hematologic cancer	3.04e-05	0.0002	CcSEcCtD
Amphetamine—Anorexia—Methotrexate—hematologic cancer	3.04e-05	0.0002	CcSEcCtD
Amphetamine—Urticaria—Prednisone—hematologic cancer	3.03e-05	0.000199	CcSEcCtD
Amphetamine—Headache—Triamcinolone—hematologic cancer	3.02e-05	0.000199	CcSEcCtD
Amphetamine—Body temperature increased—Prednisone—hematologic cancer	3.01e-05	0.000198	CcSEcCtD
Amphetamine—Abdominal pain—Prednisone—hematologic cancer	3.01e-05	0.000198	CcSEcCtD
Amphetamine—Diarrhoea—Dexamethasone—hematologic cancer	3e-05	0.000197	CcSEcCtD
Amphetamine—Diarrhoea—Betamethasone—hematologic cancer	3e-05	0.000197	CcSEcCtD
Amphetamine—Palpitations—Doxorubicin—hematologic cancer	2.99e-05	0.000196	CcSEcCtD
Amphetamine—Anaphylactic shock—Epirubicin—hematologic cancer	2.98e-05	0.000196	CcSEcCtD
Amphetamine—Infection—Epirubicin—hematologic cancer	2.96e-05	0.000195	CcSEcCtD
Amphetamine—Convulsion—Doxorubicin—hematologic cancer	2.93e-05	0.000192	CcSEcCtD
Amphetamine—Hypertension—Doxorubicin—hematologic cancer	2.92e-05	0.000192	CcSEcCtD
Amphetamine—Tachycardia—Epirubicin—hematologic cancer	2.91e-05	0.000191	CcSEcCtD
Amphetamine—Dizziness—Betamethasone—hematologic cancer	2.9e-05	0.00019	CcSEcCtD
Amphetamine—Dizziness—Dexamethasone—hematologic cancer	2.9e-05	0.00019	CcSEcCtD
Amphetamine—Hyperhidrosis—Epirubicin—hematologic cancer	2.88e-05	0.000189	CcSEcCtD
Amphetamine—Insomnia—Methotrexate—hematologic cancer	2.88e-05	0.000189	CcSEcCtD
Amphetamine—Chest pain—Doxorubicin—hematologic cancer	2.88e-05	0.000189	CcSEcCtD
Amphetamine—Anxiety—Doxorubicin—hematologic cancer	2.87e-05	0.000188	CcSEcCtD
Amphetamine—Nausea—Triamcinolone—hematologic cancer	2.87e-05	0.000188	CcSEcCtD
Amphetamine—Anorexia—Epirubicin—hematologic cancer	2.84e-05	0.000187	CcSEcCtD
Amphetamine—Dyspnoea—Methotrexate—hematologic cancer	2.84e-05	0.000187	CcSEcCtD
Amphetamine—Somnolence—Methotrexate—hematologic cancer	2.83e-05	0.000186	CcSEcCtD
Amphetamine—Dry mouth—Doxorubicin—hematologic cancer	2.82e-05	0.000185	CcSEcCtD
Amphetamine—Hypersensitivity—Prednisone—hematologic cancer	2.81e-05	0.000185	CcSEcCtD
Amphetamine—Dyspepsia—Methotrexate—hematologic cancer	2.81e-05	0.000184	CcSEcCtD
Amphetamine—Vomiting—Dexamethasone—hematologic cancer	2.78e-05	0.000183	CcSEcCtD
Amphetamine—Vomiting—Betamethasone—hematologic cancer	2.78e-05	0.000183	CcSEcCtD
Amphetamine—Decreased appetite—Methotrexate—hematologic cancer	2.77e-05	0.000182	CcSEcCtD
Amphetamine—Rash—Dexamethasone—hematologic cancer	2.76e-05	0.000181	CcSEcCtD
Amphetamine—Rash—Betamethasone—hematologic cancer	2.76e-05	0.000181	CcSEcCtD
Amphetamine—Anaphylactic shock—Doxorubicin—hematologic cancer	2.76e-05	0.000181	CcSEcCtD
Amphetamine—Dermatitis—Dexamethasone—hematologic cancer	2.76e-05	0.000181	CcSEcCtD
Amphetamine—Dermatitis—Betamethasone—hematologic cancer	2.76e-05	0.000181	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.75e-05	0.000181	CcSEcCtD
Amphetamine—Fatigue—Methotrexate—hematologic cancer	2.75e-05	0.000181	CcSEcCtD
Amphetamine—Headache—Dexamethasone—hematologic cancer	2.74e-05	0.00018	CcSEcCtD
Amphetamine—Headache—Betamethasone—hematologic cancer	2.74e-05	0.00018	CcSEcCtD
Amphetamine—Infection—Doxorubicin—hematologic cancer	2.74e-05	0.00018	CcSEcCtD
Amphetamine—Asthenia—Prednisone—hematologic cancer	2.74e-05	0.00018	CcSEcCtD
Amphetamine—Insomnia—Epirubicin—hematologic cancer	2.7e-05	0.000177	CcSEcCtD
Amphetamine—Tachycardia—Doxorubicin—hematologic cancer	2.69e-05	0.000177	CcSEcCtD
Amphetamine—Hyperhidrosis—Doxorubicin—hematologic cancer	2.67e-05	0.000175	CcSEcCtD
Amphetamine—Dyspnoea—Epirubicin—hematologic cancer	2.66e-05	0.000175	CcSEcCtD
Amphetamine—Somnolence—Epirubicin—hematologic cancer	2.65e-05	0.000174	CcSEcCtD
Amphetamine—Anorexia—Doxorubicin—hematologic cancer	2.63e-05	0.000173	CcSEcCtD
Amphetamine—Dyspepsia—Epirubicin—hematologic cancer	2.63e-05	0.000172	CcSEcCtD
Amphetamine—Diarrhoea—Prednisone—hematologic cancer	2.61e-05	0.000171	CcSEcCtD
Amphetamine—Gastrointestinal pain—Methotrexate—hematologic cancer	2.61e-05	0.000171	CcSEcCtD
Amphetamine—Nausea—Dexamethasone—hematologic cancer	2.6e-05	0.000171	CcSEcCtD
Amphetamine—Nausea—Betamethasone—hematologic cancer	2.6e-05	0.000171	CcSEcCtD
Amphetamine—Decreased appetite—Epirubicin—hematologic cancer	2.59e-05	0.00017	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.58e-05	0.000169	CcSEcCtD
Amphetamine—Fatigue—Epirubicin—hematologic cancer	2.57e-05	0.000169	CcSEcCtD
Amphetamine—Constipation—Epirubicin—hematologic cancer	2.55e-05	0.000168	CcSEcCtD
Amphetamine—Urticaria—Methotrexate—hematologic cancer	2.53e-05	0.000166	CcSEcCtD
Amphetamine—Dizziness—Prednisone—hematologic cancer	2.52e-05	0.000166	CcSEcCtD
Amphetamine—Abdominal pain—Methotrexate—hematologic cancer	2.52e-05	0.000166	CcSEcCtD
Amphetamine—Body temperature increased—Methotrexate—hematologic cancer	2.52e-05	0.000166	CcSEcCtD
Amphetamine—Insomnia—Doxorubicin—hematologic cancer	2.5e-05	0.000164	CcSEcCtD
Amphetamine—Dyspnoea—Doxorubicin—hematologic cancer	2.46e-05	0.000162	CcSEcCtD
Amphetamine—Somnolence—Doxorubicin—hematologic cancer	2.45e-05	0.000161	CcSEcCtD
Amphetamine—Gastrointestinal pain—Epirubicin—hematologic cancer	2.44e-05	0.00016	CcSEcCtD
Amphetamine—Dyspepsia—Doxorubicin—hematologic cancer	2.43e-05	0.00016	CcSEcCtD
Amphetamine—Vomiting—Prednisone—hematologic cancer	2.42e-05	0.000159	CcSEcCtD
Amphetamine—Rash—Prednisone—hematologic cancer	2.4e-05	0.000158	CcSEcCtD
Amphetamine—Dermatitis—Prednisone—hematologic cancer	2.4e-05	0.000158	CcSEcCtD
Amphetamine—Decreased appetite—Doxorubicin—hematologic cancer	2.4e-05	0.000158	CcSEcCtD
Amphetamine—Headache—Prednisone—hematologic cancer	2.39e-05	0.000157	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.38e-05	0.000157	CcSEcCtD
Amphetamine—Fatigue—Doxorubicin—hematologic cancer	2.38e-05	0.000156	CcSEcCtD
Amphetamine—Urticaria—Epirubicin—hematologic cancer	2.37e-05	0.000156	CcSEcCtD
Amphetamine—Constipation—Doxorubicin—hematologic cancer	2.36e-05	0.000155	CcSEcCtD
Amphetamine—Body temperature increased—Epirubicin—hematologic cancer	2.36e-05	0.000155	CcSEcCtD
Amphetamine—Abdominal pain—Epirubicin—hematologic cancer	2.36e-05	0.000155	CcSEcCtD
Amphetamine—Hypersensitivity—Methotrexate—hematologic cancer	2.35e-05	0.000154	CcSEcCtD
Amphetamine—Asthenia—Methotrexate—hematologic cancer	2.29e-05	0.00015	CcSEcCtD
Amphetamine—Nausea—Prednisone—hematologic cancer	2.27e-05	0.000149	CcSEcCtD
Amphetamine—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.26e-05	0.000148	CcSEcCtD
Amphetamine—Hypersensitivity—Epirubicin—hematologic cancer	2.2e-05	0.000144	CcSEcCtD
Amphetamine—Urticaria—Doxorubicin—hematologic cancer	2.19e-05	0.000144	CcSEcCtD
Amphetamine—Abdominal pain—Doxorubicin—hematologic cancer	2.18e-05	0.000143	CcSEcCtD
Amphetamine—Body temperature increased—Doxorubicin—hematologic cancer	2.18e-05	0.000143	CcSEcCtD
Amphetamine—Diarrhoea—Methotrexate—hematologic cancer	2.18e-05	0.000143	CcSEcCtD
Amphetamine—Asthenia—Epirubicin—hematologic cancer	2.14e-05	0.000141	CcSEcCtD
Amphetamine—Dizziness—Methotrexate—hematologic cancer	2.11e-05	0.000138	CcSEcCtD
Amphetamine—Diarrhoea—Epirubicin—hematologic cancer	2.04e-05	0.000134	CcSEcCtD
Amphetamine—Hypersensitivity—Doxorubicin—hematologic cancer	2.03e-05	0.000134	CcSEcCtD
Amphetamine—Vomiting—Methotrexate—hematologic cancer	2.03e-05	0.000133	CcSEcCtD
Amphetamine—Rash—Methotrexate—hematologic cancer	2.01e-05	0.000132	CcSEcCtD
Amphetamine—Dermatitis—Methotrexate—hematologic cancer	2.01e-05	0.000132	CcSEcCtD
Amphetamine—Headache—Methotrexate—hematologic cancer	2e-05	0.000131	CcSEcCtD
Amphetamine—Asthenia—Doxorubicin—hematologic cancer	1.98e-05	0.00013	CcSEcCtD
Amphetamine—Dizziness—Epirubicin—hematologic cancer	1.97e-05	0.00013	CcSEcCtD
Amphetamine—Vomiting—Epirubicin—hematologic cancer	1.9e-05	0.000125	CcSEcCtD
Amphetamine—Nausea—Methotrexate—hematologic cancer	1.89e-05	0.000124	CcSEcCtD
Amphetamine—Diarrhoea—Doxorubicin—hematologic cancer	1.89e-05	0.000124	CcSEcCtD
Amphetamine—Rash—Epirubicin—hematologic cancer	1.88e-05	0.000124	CcSEcCtD
Amphetamine—Dermatitis—Epirubicin—hematologic cancer	1.88e-05	0.000123	CcSEcCtD
Amphetamine—Headache—Epirubicin—hematologic cancer	1.87e-05	0.000123	CcSEcCtD
Amphetamine—Dizziness—Doxorubicin—hematologic cancer	1.83e-05	0.00012	CcSEcCtD
Amphetamine—Nausea—Epirubicin—hematologic cancer	1.77e-05	0.000116	CcSEcCtD
Amphetamine—Vomiting—Doxorubicin—hematologic cancer	1.75e-05	0.000115	CcSEcCtD
Amphetamine—Rash—Doxorubicin—hematologic cancer	1.74e-05	0.000114	CcSEcCtD
Amphetamine—Dermatitis—Doxorubicin—hematologic cancer	1.74e-05	0.000114	CcSEcCtD
Amphetamine—Headache—Doxorubicin—hematologic cancer	1.73e-05	0.000114	CcSEcCtD
Amphetamine—Nausea—Doxorubicin—hematologic cancer	1.64e-05	0.000108	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—AKT1—hematologic cancer	6.99e-06	0.0001	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCG2—hematologic cancer	6.98e-06	9.98e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MTR—hematologic cancer	6.98e-06	9.98e-05	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—hematologic cancer	6.97e-06	9.96e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RGS2—hematologic cancer	6.96e-06	9.95e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CMA1—hematologic cancer	6.89e-06	9.84e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TRH—hematologic cancer	6.89e-06	9.84e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TRIO—hematologic cancer	6.89e-06	9.84e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ENO2—hematologic cancer	6.85e-06	9.79e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EP300—hematologic cancer	6.84e-06	9.77e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTAP—hematologic cancer	6.82e-06	9.74e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AGO2—hematologic cancer	6.74e-06	9.63e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SPHK1—hematologic cancer	6.74e-06	9.63e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HDAC9—hematologic cancer	6.67e-06	9.53e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LPAR1—hematologic cancer	6.67e-06	9.53e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SRC—hematologic cancer	6.65e-06	9.5e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTT1—hematologic cancer	6.64e-06	9.49e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—H3F3B—hematologic cancer	6.6e-06	9.44e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MTHFR—hematologic cancer	6.49e-06	9.28e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SDC1—hematologic cancer	6.49e-06	9.28e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—hematologic cancer	6.48e-06	9.26e-05	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—HRAS—hematologic cancer	6.45e-06	9.22e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CG—hematologic cancer	6.45e-06	9.22e-05	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—hematologic cancer	6.45e-06	9.22e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STAT3—hematologic cancer	6.41e-06	9.16e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NRAS—hematologic cancer	6.4e-06	9.14e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GRB2—hematologic cancer	6.37e-06	9.11e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CSF2—hematologic cancer	6.27e-06	8.96e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PDE4B—hematologic cancer	6.14e-06	8.77e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CNR2—hematologic cancer	6.14e-06	8.77e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK3—hematologic cancer	6.13e-06	8.76e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGF19—hematologic cancer	6.09e-06	8.7e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—FHL2—hematologic cancer	6.08e-06	8.68e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PRKCG—hematologic cancer	6.05e-06	8.65e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—JAK1—hematologic cancer	6.05e-06	8.65e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RAC2—hematologic cancer	6.04e-06	8.63e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DKK1—hematologic cancer	5.99e-06	8.56e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CREBBP—hematologic cancer	5.98e-06	8.55e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AGRN—hematologic cancer	5.96e-06	8.52e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MYC—hematologic cancer	5.96e-06	8.52e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT5B—hematologic cancer	5.94e-06	8.5e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TGFB1—hematologic cancer	5.94e-06	8.49e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADCY7—hematologic cancer	5.77e-06	8.25e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CSF2—hematologic cancer	5.69e-06	8.14e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CD—hematologic cancer	5.67e-06	8.1e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL2RA—hematologic cancer	5.65e-06	8.08e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HMMR—hematologic cancer	5.65e-06	8.07e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—IDH2—hematologic cancer	5.65e-06	8.07e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—XIAP—hematologic cancer	5.61e-06	8.02e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ALB—hematologic cancer	5.6e-06	8e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CD44—hematologic cancer	5.52e-06	7.89e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NQO1—hematologic cancer	5.52e-06	7.89e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KRAS—hematologic cancer	5.5e-06	7.87e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—JAK1—hematologic cancer	5.49e-06	7.85e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PRKCG—hematologic cancer	5.49e-06	7.85e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SH2B3—hematologic cancer	5.47e-06	7.82e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SMARCA4—hematologic cancer	5.47e-06	7.82e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CG—hematologic cancer	5.46e-06	7.8e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GZMB—hematologic cancer	5.44e-06	7.77e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3R1—hematologic cancer	5.35e-06	7.65e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ARNTL—hematologic cancer	5.31e-06	7.59e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CTNNA1—hematologic cancer	5.31e-06	7.59e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EIF4EBP1—hematologic cancer	5.28e-06	7.54e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL3—hematologic cancer	5.28e-06	7.54e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HSPB1—hematologic cancer	5.28e-06	7.54e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYCS—hematologic cancer	5.22e-06	7.46e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SDC1—hematologic cancer	5.22e-06	7.46e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTHLH—hematologic cancer	5.22e-06	7.46e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HSP90AA1—hematologic cancer	5.19e-06	7.42e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CA9—hematologic cancer	5.17e-06	7.38e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ACP5—hematologic cancer	5.17e-06	7.38e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL2RA—hematologic cancer	5.13e-06	7.33e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NCOR2—hematologic cancer	5.1e-06	7.29e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTGER4—hematologic cancer	5.08e-06	7.26e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CREBBP—hematologic cancer	5.06e-06	7.23e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PIK3CA—hematologic cancer	5.06e-06	7.23e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LCK—hematologic cancer	5.05e-06	7.22e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—H3F3A—hematologic cancer	4.95e-06	7.08e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CB—hematologic cancer	4.94e-06	7.06e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—hematologic cancer	4.89e-06	6.99e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—IDH1—hematologic cancer	4.86e-06	6.94e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PRKCZ—hematologic cancer	4.82e-06	6.88e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCC3—hematologic cancer	4.8e-06	6.87e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TXN—hematologic cancer	4.8e-06	6.87e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTO1—hematologic cancer	4.8e-06	6.87e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CD—hematologic cancer	4.8e-06	6.85e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ALB—hematologic cancer	4.73e-06	6.77e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CG—hematologic cancer	4.71e-06	6.73e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SPHK1—hematologic cancer	4.7e-06	6.72e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HRAS—hematologic cancer	4.68e-06	6.69e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PARP1—hematologic cancer	4.65e-06	6.65e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTP1—hematologic cancer	4.6e-06	6.58e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FBXW7—hematologic cancer	4.58e-06	6.54e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3R1—hematologic cancer	4.53e-06	6.47e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—UGT1A1—hematologic cancer	4.52e-06	6.45e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HDAC2—hematologic cancer	4.49e-06	6.41e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCR4—hematologic cancer	4.49e-06	6.41e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—hematologic cancer	4.48e-06	6.4e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC22A1—hematologic cancer	4.39e-06	6.28e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CRABP1—hematologic cancer	4.39e-06	6.28e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CBL—hematologic cancer	4.37e-06	6.25e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCB1—hematologic cancer	4.36e-06	6.23e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL3—hematologic cancer	4.33e-06	6.18e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALOX5—hematologic cancer	4.28e-06	6.12e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CG—hematologic cancer	4.27e-06	6.11e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTEN—hematologic cancer	4.27e-06	6.1e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTPN1—hematologic cancer	4.25e-06	6.08e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTM1—hematologic cancer	4.23e-06	6.05e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NCOR1—hematologic cancer	4.23e-06	6.05e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PTPN11—hematologic cancer	4.2e-06	6e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RASGRP1—hematologic cancer	4.18e-06	5.98e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CB—hematologic cancer	4.18e-06	5.97e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SYK—hematologic cancer	4.17e-06	5.96e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HSP90AA1—hematologic cancer	4.17e-06	5.96e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NUP98—hematologic cancer	4.15e-06	5.93e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CD—hematologic cancer	4.14e-06	5.91e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKT1—hematologic cancer	4.13e-06	5.91e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—EP300—hematologic cancer	4.07e-06	5.82e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CREB1—hematologic cancer	4.07e-06	5.82e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ADCY7—hematologic cancer	4.03e-06	5.75e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NCOA3—hematologic cancer	4.03e-06	5.75e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT1—hematologic cancer	4.02e-06	5.75e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NUP214—hematologic cancer	4e-06	5.71e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL2—hematologic cancer	3.98e-06	5.69e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6R—hematologic cancer	3.97e-06	5.67e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCG2—hematologic cancer	3.92e-06	5.6e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTR—hematologic cancer	3.92e-06	5.6e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3R1—hematologic cancer	3.91e-06	5.58e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ENO2—hematologic cancer	3.84e-06	5.49e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—JAK2—hematologic cancer	3.8e-06	5.43e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAP2K1—hematologic cancer	3.78e-06	5.41e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GRB2—hematologic cancer	3.76e-06	5.38e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CD—hematologic cancer	3.76e-06	5.37e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PDGFA—hematologic cancer	3.75e-06	5.37e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MTHFR—hematologic cancer	3.74e-06	5.34e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTT1—hematologic cancer	3.72e-06	5.32e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KITLG—hematologic cancer	3.7e-06	5.29e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SDC1—hematologic cancer	3.64e-06	5.2e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT5A—hematologic cancer	3.62e-06	5.17e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTEN—hematologic cancer	3.61e-06	5.16e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CB—hematologic cancer	3.61e-06	5.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN2B—hematologic cancer	3.59e-06	5.12e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3R1—hematologic cancer	3.55e-06	5.07e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CD86—hematologic cancer	3.47e-06	4.96e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—JAK2—hematologic cancer	3.45e-06	4.93e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—EP300—hematologic cancer	3.44e-06	4.92e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HES1—hematologic cancer	3.42e-06	4.89e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NCOR1—hematologic cancer	3.4e-06	4.86e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CSF2—hematologic cancer	3.36e-06	4.81e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGF1—hematologic cancer	3.36e-06	4.81e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FOXO1—hematologic cancer	3.31e-06	4.74e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL2—hematologic cancer	3.31e-06	4.73e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PDGFRB—hematologic cancer	3.31e-06	4.73e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CB—hematologic cancer	3.28e-06	4.68e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PDGFRA—hematologic cancer	3.26e-06	4.65e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PRKCG—hematologic cancer	3.25e-06	4.64e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—JAK1—hematologic cancer	3.25e-06	4.64e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CG—hematologic cancer	3.14e-06	4.49e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NQO1—hematologic cancer	3.1e-06	4.42e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CD44—hematologic cancer	3.1e-06	4.42e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL2RA—hematologic cancer	3.03e-06	4.33e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CA—hematologic cancer	3.01e-06	4.31e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL2—hematologic cancer	3.01e-06	4.3e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TERT—hematologic cancer	3e-06	4.28e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYCS—hematologic cancer	2.93e-06	4.19e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PDGFB—hematologic cancer	2.93e-06	4.18e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CREBBP—hematologic cancer	2.91e-06	4.16e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	2.91e-06	4.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TSC2—hematologic cancer	2.86e-06	4.09e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CD—hematologic cancer	2.76e-06	3.95e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGFR3—hematologic cancer	2.75e-06	3.93e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALB—hematologic cancer	2.73e-06	3.9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK14—hematologic cancer	2.72e-06	3.89e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ESR1—hematologic cancer	2.67e-06	3.82e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FN1—hematologic cancer	2.64e-06	3.77e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3R1—hematologic cancer	2.61e-06	3.73e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NFKBIA—hematologic cancer	2.61e-06	3.73e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—BAD—hematologic cancer	2.61e-06	3.73e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NOTCH1—hematologic cancer	2.58e-06	3.69e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.58e-06	3.69e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CA—hematologic cancer	2.55e-06	3.64e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CD80—hematologic cancer	2.53e-06	3.62e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CG—hematologic cancer	2.53e-06	3.61e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KIT—hematologic cancer	2.53e-06	3.61e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NRAS—hematologic cancer	2.53e-06	3.61e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTPN11—hematologic cancer	2.48e-06	3.55e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKT1—hematologic cancer	2.46e-06	3.52e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.44e-06	3.49e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAPK3—hematologic cancer	2.42e-06	3.46e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CB—hematologic cancer	2.41e-06	3.44e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CREB1—hematologic cancer	2.4e-06	3.44e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—BRAF—hematologic cancer	2.37e-06	3.39e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.37e-06	3.39e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.37e-06	3.39e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL2—hematologic cancer	2.35e-06	3.36e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6R—hematologic cancer	2.34e-06	3.35e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CREBBP—hematologic cancer	2.34e-06	3.35e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAP2K1—hematologic cancer	2.23e-06	3.19e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CD—hematologic cancer	2.22e-06	3.17e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CA—hematologic cancer	2.2e-06	3.14e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—KRAS—hematologic cancer	2.17e-06	3.11e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGF2—hematologic cancer	2.13e-06	3.04e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.1e-06	3e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3R1—hematologic cancer	2.1e-06	3e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKT1—hematologic cancer	2.08e-06	2.98e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTEN—hematologic cancer	2.08e-06	2.97e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—JAK2—hematologic cancer	2.04e-06	2.91e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CA—hematologic cancer	2e-06	2.85e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MDM2—hematologic cancer	1.99e-06	2.84e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—EP300—hematologic cancer	1.98e-06	2.84e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CB—hematologic cancer	1.93e-06	2.77e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MTOR—hematologic cancer	1.93e-06	2.77e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HRAS—hematologic cancer	1.85e-06	2.64e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	1.82e-06	2.6e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	1.8e-06	2.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASP3—hematologic cancer	1.78e-06	2.54e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL2—hematologic cancer	1.78e-06	2.54e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—hematologic cancer	1.77e-06	2.53e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.76e-06	2.52e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCND1—hematologic cancer	1.73e-06	2.48e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—JUN—hematologic cancer	1.73e-06	2.47e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	1.68e-06	2.4e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTEN—hematologic cancer	1.67e-06	2.39e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK8—hematologic cancer	1.64e-06	2.34e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.63e-06	2.33e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT1—hematologic cancer	1.63e-06	2.33e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EP300—hematologic cancer	1.59e-06	2.28e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SRC—hematologic cancer	1.55e-06	2.22e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.55e-06	2.21e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALB—hematologic cancer	1.53e-06	2.18e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—hematologic cancer	1.51e-06	2.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT3—hematologic cancer	1.5e-06	2.14e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NRAS—hematologic cancer	1.49e-06	2.13e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CA—hematologic cancer	1.47e-06	2.1e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.46e-06	2.09e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK3—hematologic cancer	1.43e-06	2.04e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MYC—hematologic cancer	1.39e-06	1.99e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TGFB1—hematologic cancer	1.39e-06	1.98e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.35e-06	1.93e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KRAS—hematologic cancer	1.28e-06	1.83e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKT1—hematologic cancer	1.2e-06	1.71e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	1.18e-06	1.69e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTEN—hematologic cancer	1.17e-06	1.67e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—hematologic cancer	1.14e-06	1.63e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—EP300—hematologic cancer	1.11e-06	1.59e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HRAS—hematologic cancer	1.09e-06	1.56e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—hematologic cancer	1.04e-06	1.49e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT1—hematologic cancer	9.64e-07	1.38e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	8.23e-07	1.18e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKT1—hematologic cancer	6.72e-07	9.61e-06	CbGpPWpGaD
